A study to compare different doses of MSTT1041A with a “placebo” – in patients with severe asthma

A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Uncontrolled Severe Asthma

  • Respiratory Disorder
  • Asthma
Please note that the recruitment status of the trial at your site may differ from the overall study status because some study sites may recruit earlier than others.
Trial Status:

Completed

This trial runs in
Cities
  • Brampton
  • Mississauga
  • Québec
  • Toronto
  • Windsor
Trial Identifier:

NCT02918019 2016-001549-13 GB39242

      Show trial locations

      The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical trial see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.

      The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

      Results Disclaimer

      Trial Summary

      This is a Phase IIb, randomized, placebo-controlled, double-blind, multicenter, multi-arm study which will evaluate efficacy, safety, and pharmacokinetic of MSTT1041A compared with placebo as add-on therapy in participants with severe, uncontrolled asthma who are receiving medium- or high-dose inhaled corticosteroid (ICS) therapy and at least one of the following additional controller medications: long-acting beta-agonists (LABA), leukotriene modifier (LTM), long-acting muscarinic antagonist (LAMA), or long-acting theophylline preparation. The total duration of this study for each participant is approximately 70 weeks including screening, run-in, treatment, and follow-up.

      Hoffmann-La Roche Sponsor
      Phase 2 Phase
      NCT02918019, GB39242, 2016-001549-13 Trial Identifier
      MSTT1041A, Placebo Treatments
      Asthma Condition
      Official Title

      A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Study to Assess the Efficacy and Safety of MSTT1041A in Patients With Uncontrolled Severe Asthma

      Eligibility Criteria

      All Gender
      ≥18 Years & ≤ 75 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Body mass index (BMI) of 18 to 38 kilogram/square meter (kg/m^2) and weight >= 40 kg at screening
      • Documented physician-diagnosed asthma
      • On high dose inhaled corticosteroid (ICS) therapy plus at least one additional allowed controller medication
      • Forced expiratory volume in 1 second (FEV1) of 40% to 80% of predicted
      • Evidence of uncontrolled asthma
      • Use of contraceptive measures
      Exclusion Criteria
      • Diagnosis of mimics of asthma
      • Diagnosis of occupational asthma, aspirin-sensitive asthma, asthma chronic obstructive pulmonary disease overlap syndrome, or bronchiolitis, as determined by the investigator
      • Pregnant or lactating, or intending to become pregnant during the study or within 20 weeks after the last dose of MSTT1041A
      • Recent history of smoking
      • History or evidence of substance abuse that would pose a risk to participants safety, interfere with the conduct of the study, have an impact on the study results
      • Asthma exacerbation within 4 weeks prior to screening
      • Intubation for respiratory failure due to asthma within 12 months prior to screening
      • Comorbid conditions that may interfere with evaluation of investigational medicinal product
      • Known sensitivity to any of the active substances or their excipients to be administered during dosing
      • Positive pregnancy test

      For the latest version of this information please go to www.forpatients.roche.com

       

      Related Trials

      Use our search to find other trials on FindRocheTrials in related disease areas.

      Asthma

      Clinical Research Explained

      Information about what clinical trials and observational studies are. Understand why you might want to take part in clinical research and why diversity in clinical research is important.

      Find out now